Results 11 to 20 of about 232,776 (304)

Serum fibroblast growth factor 23 and kidney injury molecule-1 in the prediction of acute kidney injury in critically-ill patients. [PDF]

Ren Fail
Zhang L, Wang L, Yan B, Pei X, Wang N, Yan L, Cao H, Shao F.   +7 more
europepmc   +2 more sources

High intact fibroblast growth factor 23 levels associated with low hemoglobin levels in patients on chronic hemodialysis

Frontiers in Medicine, 2023
IntroductionA negative association between C-terminal fibroblast growth factor 23 (cFGF23) and hemoglobin (Hb) levels has been reported in patients with predialysis chronic kidney disease.
Yu-Wei Fang, Yu-Wei Fang, Jing-Tong Wang, Tzu Yun Lin, Chung-Jen Lee, Tsrang-Neng Jang, Tsrang-Neng Jang, Ming-Hsien Tsai, Ming-Hsien Tsai, Hung-Hsiang Liou   +9 more
doaj   +1 more source

Fibroblast Growth Factor 23 Is a Strong Predictor of Adverse Events After Left Ventricular Assist Device Implantation. [PDF]

J Cardiovasc Dev Dis
Yared W, Dogan L, Fassli AM, Moza A, Goetzenich A, Stoppe C, Mohammed AFA, Kraemer S, Tewarie L, Abugameh A, Zayat R.   +10 more
europepmc   +3 more sources

Skeletal FGFR1 signaling is necessary for regulation of serum phosphate level by FGF23 and normal life span

Biochemistry and Biophysics Reports, 2021
Fibroblast growth factor (FGF) 23 produced by the bone is the principal hormone to regulate serum phosphate level. Serum FGF23 needs to be tightly regulated to maintain serum phosphate in a narrow range.
Yuichi Takashi, Shun Sawatsubashi, Itsuro Endo, Yukiyo Ohnishi, Masahiro Abe, Munehide Matsuhisa, Daiji Kawanami, Toshio Matsumoto, Seiji Fukumoto   +8 more
doaj   +1 more source

Tumor-induced osteomalacia: Easing the diagnosis with fibroblast growth factor 23

APIK Journal of Internal Medicine, 2022
Tumor-induced osteomalacia (TIO), is a rare paraneoplastic syndrome resulting in bone pain, muscle weakness, and recurrent fractures. Hypophosphatemia, hyperphosphaturia, low 1, 25 dihydroxyVitamin D, and normal serum calcium are noted.
Mala Dharmalingam, Lohit Kumbar
doaj   +1 more source

Effects of Single Vitamin D Injection (200,000 Units) on Serum Fibroblast Growth Factor 23 and Sclerostin Levels in Subjects with Vitamin D Deficiency [PDF]

Endocrinology and Metabolism, 2017
BackgroundVitamin D deficiency remains common in all age groups and affects skeletal and non-skeletal health. Fibroblast growth factor 23 is a bone-derived hormone that regulates phosphate and 1,25-dihydroxyvitamin D homeostasis as a counter regulatory ...
Dongdong Zhang, Da Hea Seo, Han Seok Choi, Hye-Sun Park, Yoon-Sok Chung, Sung-Kil Lim   +5 more
doaj   +1 more source

How Fibroblast Growth Factor 23 Works [PDF]

Journal of the American Society of Nephrology, 2007
There is a discontinuum of hereditary and acquired disorders of phosphate homeostasis that are caused by either high or low circulating levels of the novel phosphaturic hormone fibroblastic growth factor 23 (FGF23). Disorders that are caused by high circulating levels of FGF23 are characterized by hypophosphatemia, decreased production of 1,25 ...
Shiguang, Liu, L Darryl, Quarles
openaire   +2 more sources

Fibroblast Growth Factor 23 [PDF]

Journal of the American Society of Nephrology, 2005
Although phosphate is important in skeletal mineralization, energy metabolism, and multiple enzymatic processes, little has been understood about the regulation of phosphate in health and disease until recently.
Erik A, Imel, Michael J, Econs
openaire   +2 more sources

Fibroblast growth factor 23, klotho and heparin

Current Opinion in Nephrology & Hypertension, 2023
Purpose of review Fibroblast growth factor (FGF) 23 is a bone-derived hormone that regulates phosphate and vitamin D metabolism by targeting the kidney. When highly elevated, such as in chronic kidney disease (CKD), FGF23 can also target the heart and induce pathologic remodeling.
Thomas, S. Madison, Li, Qing, Faul, Christian   +2 more
openaire   +2 more sources

Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism

PLoS ONE, 2022
This ad hoc analysis of a previously conducted phase 3 head-to-head comparison study of evocalcet and cinacalcet in secondary hyperparathyroidism patients undergoing maintenance hemodialysis evaluated the efficacy and safety of combined once-daily oral ...
Takashi Shigematsu, Shinji Asada, Yuichi Endo, Takehisa Kawata, Masafumi Fukagawa, Tadao Akizawa   +5 more
doaj   +2 more sources